Dalkon Shield

Dalkon Shield
Name	Dalkon Shield
Type	intrauterine device
Manufacturer	A.H. Robins Company
Introduced	1970
Withdrawn	1974
Complications	pelvic infection, septic abortion, infertility
Litigation	A.H. Robins bankruptcy, Dalkon Shield litigation trust

Dalkon Shield The Dalkon Shield was a contraceptive intrauterine device introduced in 1970 that became central to major medical, legal, and regulatory controversies in the United States and internationally. Invented by an engineer and marketed by a pharmaceutical company, the device was associated with a wave of lawsuits, public health debates involving Food and Drug Administration, and shifts in reproductive rights policy. Its history intersects with figures and institutions in medicine, law, and public health during the 1970s and 1980s.

Background and development

The device originated from work by an engineer who filed patents and collaborated with private firms and medical consultants, drawing attention from manufacturers such as A. H. Robins and competitors in the contraceptive industry. Early clinical trials and market approvals involved interactions with regulatory bodies including the Food and Drug Administration, researchers at academic centers like Johns Hopkins Hospital and Mayo Clinic, and professional associations such as the American College of Obstetricians and Gynecologists. Marketing campaigns targeted practitioners connected to hospitals, clinics run by organizations like Planned Parenthood Federation of America, and family planning programs influenced by policymakers in the United States Congress and agencies such as the Department of Health, Education, and Welfare.

Design and materials

The device used novel features that differentiated it from earlier intrauterine devices marketed in Europe and Asia by companies similar to Bayer and Organon. Components included a polyethylene frame and a multifilament tailstring made from synthetic fibers developed by industrial manufacturers. Engineers and clinicians compared the Shield’s design to prior devices evaluated in trials at institutions like Columbia University, Harvard Medical School, and University of California, San Francisco, while materials science specialists referenced standards from organizations such as the American Society for Testing and Materials. Questions about sterilization procedures involved hospitals and laboratories accredited by entities like Joint Commission on Accreditation of Healthcare Organizations.

Controversy and safety concerns

Within a few years reports emerged linking the device to complications such as pelvic inflammatory disease, septic abortion, and loss of fertility, prompting investigations by the Food and Drug Administration and reviews in medical journals like The New England Journal of Medicine and The Lancet. Patient advocacy groups, including networks associated with National Organization for Women and grassroots health collectives influenced by activists from the Women's Liberation Movement, amplified survivors’ accounts and pressured elected officials such as members of United States Senate and United States House of Representatives to hold hearings. Medical expert testimony referenced studies from university centers including University of Pennsylvania and University of Michigan, while regulatory scrutiny involved inspectors from Centers for Disease Control and Prevention and analysts at Office of Technology Assessment.

Legal actions and settlements

Litigation consolidated thousands of claims in state and federal courts, featuring law firms experienced with mass torts and plaintiffs represented in multidistrict litigation overseen by judges in circuits including the Fourth Circuit and the Eastern District of Virginia. The manufacturer faced liability actions citing negligence, wrongful death, and product liability doctrines under precedents developed in cases heard by the Supreme Court of the United States and various state supreme courts. Settlement negotiations involved trustees, creditors, and bankruptcy courts—specifically filings under United States Bankruptcy Court supervision—which culminated in a large compensation fund managed by a court-appointed trust.

Impact on reproductive health policy

The controversy reshaped regulatory oversight of medical devices, contributing to legislative and administrative reforms involving the Food and Drug Administration and prompting debate among policymakers in the United States Congress about premarket approval and postmarket surveillance. Public health programs administered by agencies such as the Department of Health and Human Services and clinics funded through Medicaid reconsidered contraceptive counseling and informed consent protocols influenced by scholars at institutions like Yale School of Medicine and University of California, Los Angeles. Internationally, ministries of health in countries across Latin America, Africa, and Asia reviewed procurement policies and guidelines from agencies like the World Health Organization.

Aftermath and legacy

The aftermath included bankruptcy of the manufacturer, creation of victim compensation mechanisms, and long-term changes in tort practice, medical device regulation, and consumer safety advocacy. Legal settlements and trust funds administered under court supervision provided compensation while academic examinations of the episode informed curricula at schools such as Columbia Law School and Harvard School of Public Health. The episode remains a case study in risk management cited by regulatory bodies including the Food and Drug Administration, watchdog groups like Public Citizen, and historians of medicine at museums and archives such as the National Library of Medicine.

Category:Contraception Category:Medical controversies Category:Product liability